DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients

Keyphrases

• Breast Cancer Patients 100%
• DNA Methylation (DNAm) 100%
• Colorectal Cancer Patients 100%
• Peripheral Blood 100%
• Immune Checkpoint 100%
• TIGIT 100%
• Programmed Death-ligand 1 (PD-L1) 85%
• Primary Breast Cancer 85%
• Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) 57%
• In Cancer 42%
• Promoter Methylation 42%
• TIM-3 42%
• Cancer Patients 28%
• Hypomethylating Agents 28%
• Colorectal Cancer 28%
• Demethylation 28%
• Transcriptomic Expression 28%
• Programmed Cell Death Protein 1 (PD-1) 28%
• Immune Evasion 14%
• Epigenetic Modification 14%
• Tumor Microenvironment 14%
• Tumor Cells 14%
• Methylation Status 14%
• Therapeutic Strategies 14%
• Hypomethylation 14%
• Hypermethylated 14%
• Aberrant Expression 14%
• DNA Methylation Profiling 14%
• Healthy Donors 14%
• Tumor Tissue 14%
• Methylation Profile 14%
• Ten-eleven Translocation 1 (TET1) 14%
• Immunosuppressive Microenvironment 14%
• Anti-TIGIT 14%
• Demethylation Inhibitor 14%
• TET3 14%
• Anti-programmed Cell Death Protein 1 (anti-PD-1) 14%

Biochemistry, Genetics and Molecular Biology

• DNA Methylation 100%
• Immune Checkpoints 100%
• TIGIT 100%
• PD-L1 87%
• CTLA-4 50%
• Promoter Region 37%
• Demethylation 37%
• Methylation 25%
• Transcriptomics 25%
• Upregulation 12%
• Immune Evasion 12%
• Epigenetic Modification 12%
• Enzyme 12%